Prognostic characterization of immune molecular subtypes in non-small cell lung cancer to immunotherapy

Código QR

Prognostic characterization of immune molecular subtypes in non-small cell lung cancer to immunotherapy

Abstract Background Non-small cell lung cancer (NSCLC) was usually associated with poor prognosis and invalid therapeutical response to immunotherapy due to biological heterogeneity. It is urgent to screen reliable biomarkers, especially immunotherapy-associated biomarkers, that can predict outcomes...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chenlu Li, Jingjing Pan, Jing Luo, Xupeng Chen
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Non-small cell lung cancer Immune molecular subtype Risk stratification Immunotherapy Prognosis Diseases of the respiratory system RC705-779
Acceso en línea:	https://doaj.org/article/22ade93edf0944fea407007df5cc0fcb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Immunotherapy in patients with non-small cell lung cancer with ECOG PS 2
por: Damian Mojsak, et al.
Publicado: (2021)

5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer
por: Jiao Hu, et al.
Publicado: (2021)

Combined treatment of non‐small cell lung cancer using radiotherapy and immunotherapy: challenges and updates
por: Shijie Shang, et al.
Publicado: (2021)

Small cell transformation of non‐small cell lung cancer under immunotherapy: Case series and literature review
por: Takuma Imakita, et al.
Publicado: (2021)

Factors associated with immunotherapy respond and survival in advanced non-small cell lung cancer patients
por: Yahua Wu, et al.
Publicado: (2022)

Identification and Validation of an Immune and Ferroptosis-Combined Index for Non–Small Cell Lung Cancer
por: Yang Teng, et al.
Publicado: (2021)

Mutational signature analysis in non-small cell lung cancer patients with a high tumor mutational burden
por: Guus R. M. van den Heuvel, et al.
Publicado: (2021)

Comprehensive Analysis of Subtype-Specific Molecular Characteristics of Colon Cancer: Specific Genes, Driver Genes, Signaling Pathways, and Immunotherapy Responses
por: Fangjie Hu, et al.
Publicado: (2021)

Impact of Chronic Obstructive Pulmonary Disease on the Mortality of Patients with Small Cell Lung Cancer
por: Liao KM, et al.
Publicado: (2021)

The effects of inhaling hydrogen gas on macrophage polarization, fibrosis, and lung function in mice with bleomycin-induced lung injury
por: Toshiyuki Aokage, et al.
Publicado: (2021)

Identification of Two Molecular Subtypes of Hepatocellular Carcinoma Based on Dysregulated Immune LncRNAs
por: Hongsheng Lin, et al.
Publicado: (2021)

Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis
por: Valerio Nardone, et al.
Publicado: (2021)

Potential Immune Biomarker Candidates and Immune Subtypes of Lung Adenocarcinoma for Developing mRNA Vaccines
por: Yang Wang, et al.
Publicado: (2021)

Programmed death-ligand 1 expression and tumor-infiltrating lymphocytes in non-small cell lung cancer: association with clinicopathologic parameters
por: Gaurav Garg, et al.
Publicado: (2021)

Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China
por: Anwen Xiong, et al.
Publicado: (2021)

Crossed Pathways for Radiation-Induced and Immunotherapy-Related Lung Injury
por: Zengfu Zhang, et al.
Publicado: (2021)

Metabolic Signature-Based Subtypes May Pave Novel Ways for Low-Grade Glioma Prognosis and Therapy
por: Ganglei Li, et al.
Publicado: (2021)

Prognostic Implications and Immune Infiltration Analysis of ALDOA in Lung Adenocarcinoma
por: Guojun Lu, et al.
Publicado: (2021)

Validation of the risk stratification score in idiopathic pulmonary fibrosis: study protocol of a prospective, multi-centre, observational, 3-year clinical trial
por: Gian Marco Manzetti, et al.
Publicado: (2021)

LRMP Associates With Immune Infiltrates and Acts as a Prognostic Biomarker in Lung Adenocarcinoma
por: Xin Jin, et al.
Publicado: (2021)

Clinical case of long-term use of durvalumab in the treatment of advanced small-cell lung cancer
por: Galina B. Statsenko, et al.
Publicado: (2020)

Advances in Biomarkers for Immunotherapy of Non-small Cell Lung Cancer
por: Chuan HUANG, et al.
Publicado: (2021)

m6A regulator expression profile predicts the prognosis, benefit of adjuvant chemotherapy, and response to anti-PD-1 immunotherapy in patients with small-cell lung cancer
por: Zhihui Zhang, et al.
Publicado: (2021)

Encephalitis in non-small-cell lung cancer
por: M. Costa e Silva, et al.
Publicado: (2021)

Development of a Prognostic Nomogram for Patients with Lung Adenocarcinoma in the Stages I, II, and III Based on Immune Scores
por: Xie H, et al.
Publicado: (2021)

Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management
por: Maja Šutić, et al.
Publicado: (2021)

Identification and Validation of the Pyroptosis-Related Molecular Subtypes of Lung Adenocarcinoma by Bioinformatics and Machine Learning
por: Le-Ping Liu, et al.
Publicado: (2021)

Immunotherapy-Related Cardiotoxicity Re-Emergence in Non-Small Cell Lung Cancer – A Case Report
por: Li Y, et al.
Publicado: (2021)

Immune Infiltration-Related Signature Predicts Risk Stratification and Immunotherapy Efficacy in Grade II and III Gliomas
por: Cong Luo, et al.
Publicado: (2021)

Comprehensive Analysis Uncovers Prognostic and Immunogenic Characteristics of Cellular Senescence for Lung Adenocarcinoma
por: Weihao Lin, et al.
Publicado: (2021)

New targeted treatments for non-small-cell lung cancer – role of nivolumab
por: Zago G, et al.
Publicado: (2016)

ANOTHER syndrome—Familial presentations of progressive lung disease leading to double lung transplantation: A case report and literature review
por: Christina S. Thornton, et al.
Publicado: (2021)

Identification of the Immune Cell Infiltration Landscape in Hepatocellular Carcinoma to Predict Prognosis and Guide Immunotherapy
por: Shiyan Yang, et al.
Publicado: (2021)

Association of expression and genotypes of thymidylate synthase in non-small cell lung cancer patients with different clinicopathological characteristics
por: Chen Jin-Yin, et al.
Publicado: (2021)

New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab
por: Seetharamu N, et al.
Publicado: (2017)

Effectiveness of Postoperative or Preoperative Radiotherapy on Prognosis in Patients with Stage II Resectable Non-Small Cell Lung Cancer: A Retrospective Study Based on the SEER Database
por: Deng Chen, et al.
Publicado: (2021)

Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer
por: Chinese Society of Clinical Oncology, Expert Committee on Tumor Vascular-targeted Therapy, et al.
Publicado: (2021)

A short primer on lung stereology
por: Matthias Ochs, et al.
Publicado: (2021)

Construction of circRNA-miRNA-mRNA network and identification of novel potential biomarkers for non-small cell lung cancer
por: Jia Yang, et al.
Publicado: (2021)

Clinical Outcomes of Chemotherapeutic Molecules as Single and Multiple Agents in Advanced Non-Small-Cell Lung Carcinoma (NSCLC) Patients
por: Ting Yoon Kwan, et al.
Publicado: (2021)